微泰医疗-B二零二三年中期报告

2 4 37 40 108 1500 108 9984 24840 1366B20235 H 1617 9792720235 2235 998 www.microtechmd.com 3 2023630110.8202263071.854.3%202363057.6202263031.881.3%202263044%202363052%AiDEXEquil 2023PanCaresAiDEX X20237 202363032.030.2%2023630(1)Equil318(2)218(3)AiDEX X(4)PanCares(5)(6)Exactive Pro20225CE (Arab Health)16(ATTD)6•92023 2023630514159CE1FDA 510(k)8 -Equil — EquilEquil20Equil2018Equil(2018)2021Equil 2023630Equil AiDEXAiDEXAiDEX2023630 — AiDEX XAiDEX X AiDEX XAiDEX 202363020235 IVD 157FDACE126 Exactive Pro — Exactive ProExactive Pro20225CEExactive Pro IVocare IVocareC 1,0005,000— 2022• 18A.08(3) 15 EquilAiDEX2023 15,000GMP 產產產2023(Arab Health)16(Advanced Technologies & Treatments forDiabetes,ATTD)(Wroclawskie Spotkania zEndokrynologia i Diabetologia Dziecieca)(HOSPITALAR 2023)(CMEF) 6 · 9 2023630110.8202263071.854.3%AiDEXEquil 202363053.2202263040.132.8% 202363057.6202263031.881.3%202263044%202363052% 202263039.076.7%202363068.9 202263014.357.5%202363022.6 202263024.630.2%202363032.0 20222023630 202263020236307.918.7 202363020236303.08% 19 2023630 2023630 20236307.8 2023630(i)(ii) ICC 2023630 2023630 2023630742 Equil 20211.3 Equil30EquilEquilEquilEquil AiDEX AiDEX14(MARD)9.08% AiDEXTime-in RangeAiDEXEquilAiDEX EquilAiDEXAiDEX2023 2023EquilAiDEX X 2023630 C.2.1 C.2.1(i)(ii)(iii) 20236302022630 20234265182023426 20236302023630 20211019202111101,875.531,533.492023630 (2)20236301,199.7320251231 13.51B(1) 20236 30XV352 (1)2023630425,742,600173,840,442H208,205,47443,696,684 (2)L 2023630XVXV78352 2023630XV23XV336 (1)2023630425,742,600173,840,442H208,205,47443,696,684 (2)L (3)12,688,16610,466,0336,343,131H5,232,232H (4)Qiming Venture Partners V, L.P.QM32 Limited 96.99%Qiming Venture Partners V,L.P.Qiming GP V, L.P.Qiming GP V, L.P.Qiming Corporate GP V, Ltd.Qiming Venture Partners V, L.P.Qiming GP V, L.P.QimingCorporate GP V, Ltd.QM32 Limited (5)(i)3,426,804(ii)6,944,317(iii)2,472,612(iv)1,856,334 (6)LAV Evergreen (Hong Kong) Co., LimitedLilly Asia Ventures Fund II, L.P.LillyAsia Ventures Fund II, L.P.Lilly Asia Ventures Fund GP, L.P.Lilly Asia Ventures FundGP, L.P.LAV Corporate GP, Ltd.LAV StarLimitedLAV Fund VI, L.P.LAV StarOpportunities LimitedLAV Fund VI Opportunities, L.P.LAV Fund VI, L.P.LAV Fund VI(1)Lilly Asia Ventures Fund II, L.P.Lilly Asia VenturesFund GP, L.P.LAV Corporate GP, Ltd.LAV Evergreen (Hong Kong)Co., Limited17,091,680(2)LAV Star LimitedLAV Star Opportunities LimitedLAV Evergreen(Hong Kong) Co., Limited12,464,540HLAV Asset Management(Hong Kong) Limited (7)15,678,051 (8)(i)11,983,877(ii)9,792,927 (9)50%50%16,055,165XV30 (10)QM153 LimitedQiming Venture Partners VII, L.P.99.09%Qiming GP VII, LLCQiming Venture Partners VII,L.P.Qiming GP VII, LLCQM153 Limited4,458,238 2023630XV23336 18 2022H 20226222022HHH20231120236302022H8,510,000H2022H2022 20181220209212019122520209212023116302022 20236306 63020232022 1.(18,663)(7,942)2.–– 1.(18,663)(7,942)2.–– 63020232022 689– 1.––2.––3.––4.––5.––6.689–7.–––– (17,974)(7,942) (17,974)(7,942)–– 7(0.04)(0.02)7(0.04)(0.02) 202363020221231 202363020221231 202363020221231 202363020221231 20236306 63020232022 128,31980,1203,3562,97014,79729,626146,472112,71654,78461,22770,18050,84943089852,87926,197178,273139,171 63020232022 63020232022 1. 108 H20211019425,742,600425,742,60020236302023630 2. 2.1 202363062220221231 2.2 20221231 3. 4. 4. 5. 25%202225%15%202215%2.5%20222.5% 20232022 6. 20236302022630 7. 425,742,600 8. 9. 202363020221231 10. 11. 12. (a) (i) 12. (b) 13. 202363020221231 — 13. 14. 14. 202363020221231 2022630 10.92198